Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Post-menopausal Vasomotor Symptoms Clear all

Conditions: Hot Flashes, Hot Flushes, Vasomotor Symptoms
Interventions: Stellate Ganglion Block Injection with Bupivicaine, Saline injection; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years to 70 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Post-menopausal Vasomotor Symptoms
Interventions: ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID, Placebo; Drug
Lead sponsor: Acer Therapeutics Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Postmenopausal Symptoms
Interventions: Estrogel, Placebo; Drug · Other
Lead sponsor: ASCEND Therapeutics; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more

Conditions: Menopause, Hot Flashes, Night Waking
Interventions: Elinzanetant (BAY3427080), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Mesa, Arizona • San Diego, California • Aventura, Florida + 6 more

Conditions: Postmenopausal Female Patients, Vasomotor Symptoms, Menopausal Hormone Therapy
Interventions: Moderate Intensity Exercise (MIE), High intensity exercise (HIE), Control (No exercise); Other
Lead sponsor: University of Virginia; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Joint Discomfort, Joint Pain, Stiffness, Function, Joint Pain, Hot Flashes, Hot Flash, Night Sweats, Vasomotor Symptoms
Interventions: JDS-HF3.0, Placebo; Dietary Supplement · Other
Lead sponsor: Bonafide Health; Industry
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Harrison, New York

Conditions: Vasomotor Symptoms, Menopause
Interventions: FP-101; Drug
Lead sponsor: Fervent Pharmaceuticals; Industry
Eligibility: 46 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Lomita, California • Long Beach, California • West Covina, California + 8 more

Conditions: Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats, Hot Flushes, Night Sweats, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms Associated With Menopause
Interventions: JDS-HF3.0; Dietary Supplement
Lead sponsor: Bonafide Health; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Harrison, New York

Conditions: Post-menopausal Vasomotor Symptoms
Interventions: BAY3427080, Placebo (for BAY3427080); Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: DeLand, Florida • Miami, Florida • San Antonio, Texas

Conditions: Menopause, Hot Flashes
Interventions: Shatavari (Asparagus racemosus) Extract, Placebo; Dietary Supplement · Other
Lead sponsor: India Glycols Ltd; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Menopause, Menopause Hot Flashes, Menopause Related Conditions
Interventions: Haelan 951; Dietary Supplement
Lead sponsor: Spectrum Clinical Research, LLC; Network
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Vasomotor Symptoms (VMS) Associated With Menopause
Interventions: No study intervention; Other
Lead sponsor: Bayer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Obesity, Menopause Hot Flashes
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 46 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Stellate Ganglion Blockade in Post-Menopausal Women

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

Exercise Training Intensity and Nitrate Supplementation in Post-Menopausal Females on Hormone Therapy

JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)

Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women

An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity